Arianna Liparoti

Dr. Arianna Liparoti

University of Milan, Milan, Lombardy, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
Emanuele PalombaEmanuele Palomba
Emanuele Palomba
ALArianna Liparoti
Arianna Liparoti
ATAnna Tonizzo
Anna Tonizzo
VCValeria Castelli
Valeria Castelli
LALaura ALAGNA
Laura ALAGNA
ABAlessandra Bandera
Alessandra Bandera
Nocardia is primarily considered an opportunistic pathogen and affects patients with impaired immune systems, solid-organ transplant recipients (SOTRs), and patients with haematologic malignancies. We present the cases of six patients diagnosed with nocardiosis at our center in the last two years, describing the various predisposing conditions alongside the clinical manifestation, the diagnostic workup, and the treatment course. Moreover, we propose a brief literature review on Nocardia infections in the immunocompromised host, focusing on SOTRs and haematopoietic stem cell transplantation recipients and highlighting risk factors, clinical presentations, the diagnostic tools available, and current treatment and prophylaxis guidelines.

30 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
DMDavide Mangioni
Davide Mangioni
MOMassimo Oggioni
Massimo Oggioni
LCLiliane Chatenoud
Liliane Chatenoud
ALArianna Liparoti
Arianna Liparoti
SRSara Colonia Uceda Renteria
Sara Colonia Uceda Renteria
ABAlessandra Bandera
Alessandra Bandera
Coagulopathy and immune dysregulation have been identified as important causes of adverse outcomes in coronavirus disease (COVID-19). Mid-region proadrenomedullin (MR-proADM) is associated with endothelial damage and has recently been proposed as a prognostic factor in COVID-19. In non-COVID-19 immunocompromised patients, low in vitro interferon gamma (IFNγ) production correlates with infection risk and mortality. This prospective, monocentric, observational study included adult patients consecutively admitted with radiologic evidence of COVID-19 pneumonia and respiratory failure. MR-proADM and in vitro IFNγ production were measured at T0 (day 1 from admission) and T1 (day 7 from enrollment). One hundred patients were enrolled. Thirty-six percent were females, median age 65 (Q1–Q3 54.5–75) years, and 58% had ≥1 comorbidity. Only 16 patients had received COVID-19 vaccination before hospitalization. At admission, the median PaO2:FiO2 ratio was 241 (157–309) mmHg. In-hospital mortality was 13%. MR-proADM levels differed significantly between deceased and survivors both at T0 (1.41 (1.12–1.77) nmol/L vs. 0.79 (0.63–1.03) nmol/L, p < 0.001) and T1 (1.67 (1.08–1.96) nmol/L vs. 0.66 (0.53–0.95) nmol/L, p < 0.001). In vitro IFNγ production at T0 and T1 did not vary between groups. When only the subset of non-vaccinated patients was considered, both biomarkers at T1 resulted significantly associated with in-hospital mortality. AUROC for MR-proADM at T0 to predict in-hospital mortality was 0.87 (95%CI 0.79–0.94), with the best cut-off point at 1.04 nmol/L (92% sensitivity, 75% specificity and 98% negative predictive value). In patients with COVID-19 pneumonia and different degrees of respiratory failure, MR-proADM at admission and during hospitalization resulted strongly associated with in-hospital mortality. Low in vitro IFNγ production after the first week of hospitalization was associated with mortality in non-vaccinated patients possibly identifying the subgroup characterized by a higher degree of immune suppression.

20 February 2026 in Transplant Infectious Disease
Verified
Journal Article
Open access
Andrea LombardiAndrea Lombardi
Andrea Lombardi
GRGiulia Renisi
Giulia Renisi
LRLorenzo Rosso
Lorenzo Rosso
LMLetizia Morlacchi
Letizia Morlacchi
JFJacopo Fumagalli
Jacopo Fumagalli
ABAlessandra Bandera
Alessandra Bandera
Background: Lung transplantation (LuTx) is hampered by infectious risks. Perioperative antibiotic prophylaxis (PAP) is widely used; however, real‐time adjustment is hindered by the timing of standard microbiology. Syndromic molecular panels offer rapid results, yet their integration into PAP strategies remains unclear. Methods: We conducted a prospective cohort study comparing the BioFire FilmArray Pneumonia Panel Plus (PN plus ) with standard of care (SOC) on bronchoalveolar lavage (BAL) samples obtained from donors at procurement and from recipients 72 h after LuTx. Concordance between PN plus and SOC was assessed for bacterial species and antimicrobial resistance genes. Results: Fifty‐three donor‐recipient pairs were analyzed. In donor BAL, PN plus identified at least one pathogen in 67.9% (36/53) of cases versus 63.5% (33/53) by SOC, with a markedly shorter time to result (221 min vs. 5.3 days). Concordance between PN plus and SOC for bacterial species was substantial (Cohen's κ = 0.654), particularly for Staphylococcus aureus (Cohen's κ = 0.689), Streptococcus pneumoniae (Cohen's κ = 0.658), and Pseudomonas aeruginosa (Cohen's κ = 0.731). In recipient BAL, PN plus detected pathogens in 61.5% (32/53) compared to 47.2% (25/53) with SOC, but overall concordance was only moderate ( κ = 0.365). Resistance gene concordance was minimal, with PN plus often identifying additional determinants not confirmed by SOC. Viruses were detected exclusively by PN plus , while fungi were identified only by SOC. Conclusion: PN plus provides rapid, clinically relevant pathogen detection in LuTx, showing substantial agreement with SOC in donor samples and offering potential to support PAP adjustment. In early post‐transplant recipient BAL, interpretation requires caution, and SOC remains indispensable, particularly for detecting fungi and confirming phenotypic resistance. image